Back to Search
Start Over
Low cost, high temporal resolution optical fiber-based γ-photon sensor for real-time pre-clinical evaluation of cancer-targeting radiopharmaceuticals.
- Source :
-
Biosensors & bioelectronics [Biosens Bioelectron] 2024 Mar 01; Vol. 247, pp. 115956. Date of Electronic Publication: 2023 Dec 21. - Publication Year :
- 2024
-
Abstract
- Cancer radiopharmaceutical therapies (RPTs) have demonstrated great promise in the treatment of neuroendocrine and prostate cancer, giving hope to late-stage metastatic cancer patients with currently very few treatment options. These therapies have sparked a large amount of interest in pre-clinical research due to their ability to target metastatic disease, with many research efforts focused towards developing and evaluating targeted RPTs for different cancer types in in vivo models. Here we describe a method for monitoring real-time in vivo binding kinetics for the pre-clinical evaluation of cancer RPTs. Recognizing the significant heterogeneity in biodistribution of RPTs among even genetically identical animal models, this approach offers long-term monitoring of the same in vivo organism without euthanasia in contrast to ex vivo tissue dosimetry, while providing high temporal resolution with a low-cost, easily assembled platform, that is not present in small-animal SPECT/CTs. The method utilizes the developed optical fiber-based γ-photon biosensor, characterized to have a wide linear dynamic range with Lutetium-177 ( <superscript>177</superscript> Lu) activity (0.5-500 μCi/mL), a common radioisotope used in cancer RPT. The probe's ability to track in vivo uptake relative to SPECT/CT and ex vivo dosimetry techniques was verified by administering <superscript>177</superscript> Lu-PSMA-617 to mouse models bearing human prostate cancer tumors (PC3-PIP, PC3-flu). With this method for monitoring RPT uptake, it is possible to evaluate changes in tissue uptake at temporal resolutions <1 min to determine RPT biodistribution in pre-clinical models and better understand dose relationships with tumor ablation, toxicity, and recurrence when attempting to move therapies towards clinical trial validation.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Male
Animals
Mice
Humans
Radiopharmaceuticals chemistry
Radiopharmaceuticals metabolism
Radiopharmaceuticals therapeutic use
Glutamate Carboxypeptidase II
Tissue Distribution
Optical Fibers
Prostate-Specific Antigen
Lutetium chemistry
Biosensing Techniques
Prostatic Neoplasms diagnostic imaging
Prostatic Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1873-4235
- Volume :
- 247
- Database :
- MEDLINE
- Journal :
- Biosensors & bioelectronics
- Publication Type :
- Academic Journal
- Accession number :
- 38145595
- Full Text :
- https://doi.org/10.1016/j.bios.2023.115956